XERS News and Press, Xeris Pharmaceuticals Inc. From 08/29/19

CHICAGO, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that Paul R. ...

The following slide deck was published by Xeris Pharmaceuticals, Inc. in conjunction with this Read more ...

The following companies have filed prospectuses for mixed shelf offerings: More news on: Neuronetics, Inc., Xenon Pharmaceuticals Inc., Xeris Pharmaceuticals, Inc., Healthcare stocks news, Read more ...

Xeris Pharmaceuticals (NASDAQ: XERS ): Q2 GAAP EPS of -$1.28 misses by $0.32 . More news on: Xeris Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Xeris Pharmaceuticals, Inc. (NASDAQ:XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that is has dosed the first subject in a Phase 2 trial with its develop...

Xeris Pharmaceuticals' (NASDAQ: XERS ) ready-to-use glucagon auto-injector showed comparable efficacy with Novo Nordisk's GlucaGen HypoKit for achieving plasma glucose of greater than 70 mg/dl or greater than or equal to 20 mg/dl increase in glucose concentration within 30 minutes of gluco...

Findings will support application for European marketing authorization and augment body of data supporting efficacy and utility of its ready-to-use, stable liquid glucagon Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology pl...

Xeris Pharmaceuticals ( XERS ) shares sold off prior to Gvoke’s PDUFA date on June 10 th . However, the selling pressured subsided dramatically after the company reported that on June 5 th , the FDA extended Gvoke’s PDUFA date by 90 days due to a major amendment to the NDA. An FD...

Noteworthy events during the week of June 9 - 15 for healthcare investors. More news on: Merck & Co., Inc., Xeris Pharmaceuticals, Inc., Mallinckrodt plc, Healthcare stocks news, , Read more ...

The FDA has extended its action date to September 10 for its review of Xeris Pharmaceuticals' (NASDAQ: XERS ) marking application for Gvoke (ready-to-use glucagon injection) for the treatment of severe hypoglycemia (low blood sugar). More news on: Xeris Pharmaceuticals, Inc., Healthcare ...